Articles Tagged With: therapeutic
-
What Is the Right Dose of Immunoglobulin to Treat CIDP?
In this comparative trial of different doses of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy, higher doses appeared to result in a higher percentage of patients who improved. However, there was no control group and there were many confounding issues that make it difficult to reach a definitive conclusion around optimal dosing.
-
Nirmatrelvir and Ritonavir Tablets (Paxlovid)
The FDA has issued an emergency use authorization for the first oral regimen for the treatment of COVID-19.
-
FDA Authorizes Oral Antiviral for COVID-19
Clinicians add another valuable tool to their armamentarium.
-
Fluvoxamine Reduces the Risk for Hospitalization from COVID-19
Researchers found fluvoxamine (100 mg twice a day for 10 days) lowered the risk for hospitalization among high-risk outpatients diagnosed with COVID-19.
-
Study: Interferon Does Not Help Hospitalized COVID-19 Patients
When combined with remdesivir, the multiple sclerosis drug did not produce clinical benefit.
-
Vitamin D and COVID-19
Low levels of vitamin D are associated with in-hospital mortality in patients with COVID-19, but causality is unknown.
-
Bamlanivimab and Etesevimab Injection
Bamlanivimab and etesevimab should be prescribed to treat mild-to-moderate COVID-19 in adults and pediatric patients (age 12 years and older, weight at least 40 kg) who test positive for COVID-19 and are at high risk for progressing to severe disease and/or hospitalization.
-
Remdesivir Injection and Baricitinib Tablets
Baricitinib/remdesivir should be used to treat suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients ≥ age 2 years who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
-
Using Sacubitril/Valsartan to Treat Heart Failure with Preserved Ejection Fraction
An analysis of renal outcomes in the PARAGON-HF trial revealed sacubitril/valsartan slows progression of kidney disease in patients with heart failure with preserved ejection fraction compared to valsartan alone.
-
Casirivimab + Imdevimab Injection
Casirivimab/imdevimab should be used to treat mild to moderate COVID-19 in adults and patients ≥ 12 years of age weighing at least 40 kg who have tested positive for SARS-CoV-2.